Chemed drops amid report on Vista Healthcare business
Chemed (CHE) drops 4.6% after Capitol Forum report on Vista Healthcare; activist Barington urges review and board changes.
Archived explainer. For the current picture see today's CHE page.
CHEMED CORP NEW (CHE) is drawing unusual attention today. Our newswire has captured 1 story on CHE across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 34/100).
Chemed Corp New (CHE) is moving lower by 4.6% as a report from Capitol Forum on its Vista Healthcare business has triggered investor concern. The report alleges misdiagnosis of dementia patients and manipulation of evaluation scores to admit them into hospice care. Activist investor Barington Capital has called for a board review and changes in response to the findings.
The stock dropped following the Capitol Forum report, which was shared on X by the publication. The allegations center on Vista Healthcare, a key part of Chemed’s operations, and include claims of fudging patient evaluations. An expert who reviewed internal documents suggested the matter could warrant a federal investigation. In response, Barington Capital has urged Chemed to conduct a thorough review and consider board-level changes. The stock has been under pressure in the wake of the report, with retail traders and institutional investors reacting to the negative headlines.
The stock has declined 1.7% over the last eight sessions, falling from $529.23 to $520.09. Over the past 30 days, sentiment has deteriorated from an average of 54/100 to 34/100. Insiders have sold a total of $3.4 million in shares over the last 90 days, with the most recent transactions occurring on August 21 and August 3. The stock has printed eight fresh 52-week lows on August 27. Chemed’s fundamentals remain strong, with a P/E of 26.1, a revenue increase of 3.3% in the trailing twelve months, and a net margin of 10.6%. The company recently raised its full-year adjusted EPS guidance to $25.00, $25.75, above the $24.34 estimate.
Chemed’s stock is under pressure from the Capitol Forum report and activist pressure. Investors should monitor the company’s response to the allegations and any potential regulatory developments. No earnings date is provided, but coverage breadth remains active with recent analyst upgrades.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Chemed (CHE) drops 4.6% after Capitol Forum report on Vista Healthcare; activist Barington urges review and board changes.
More on CHE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CHE move explainers: 2026-08-28 · 2026-08-27